Axon Enterprise, Inc $AXON Shares Sold by Bellwether Advisors LLC

Bellwether Advisors LLC decreased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 15.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,937 shares of the biotechnology company’s stock after selling 1,112 shares during the quarter. Bellwether Advisors LLC’s holdings in Axon Enterprise were worth $4,261,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Vestor Capital LLC increased its holdings in shares of Axon Enterprise by 438,636.3% in the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after purchasing an additional 833,409 shares in the last quarter. Norges Bank acquired a new position in Axon Enterprise during the second quarter worth about $637,806,000. Vanguard Group Inc. increased its holdings in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Jennison Associates LLC increased its holdings in Axon Enterprise by 53.8% in the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares in the last quarter. Finally, 1832 Asset Management L.P. lifted its position in shares of Axon Enterprise by 129.2% during the 2nd quarter. 1832 Asset Management L.P. now owns 536,420 shares of the biotechnology company’s stock valued at $444,124,000 after acquiring an additional 302,420 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 1.2%

Axon Enterprise stock opened at $579.09 on Wednesday. The stock has a market cap of $46.56 billion, a PE ratio of 380.98, a P/E/G ratio of 12.21 and a beta of 1.46. The stock has a 50-day moving average price of $537.12 and a 200 day moving average price of $621.06. Axon Enterprise, Inc has a 52 week low of $396.41 and a 52 week high of $885.91. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s quarterly revenue was up 38.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.08 EPS. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AXON shares. Citigroup restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Piper Sandler lowered their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Barclays cut their price target on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: TD Cowen and other analysts boosted Axon’s outlook after strong bookings and continued growth in subscription/ARR, leading to an upward revision in price targets that supports the bull case. Price Target Raised After Strong Bookings Growth
• Positive Sentiment: Geopolitical headlines lifted defense-related names, including Axon, as investors favored companies exposed to public-safety and defense spending, providing near-term demand for the stock. Northrop Grumman, Axon and RTX lifted most as defense stocks gain on Iran war
• Neutral Sentiment: Axon presented at the Morgan Stanley TMT conference — management exposure at investor conferences increases visibility and can drive re-rating if they provide positive guidance, but the transcript contains no immediate market-moving surprise. Conference Presentation Transcript
• Neutral Sentiment: Recent data on short interest in the reporting snippets is anomalous/zeroed (NaN/0) and not informative — there’s no clear short squeeze signal from that data as published.
• Neutral Sentiment: Post-earnings coverage highlights a strong growth story (Axon 911, ARR growth) but also flags a very high forward earnings multiple, implying the stock needs near-perfect execution to justify the premium. This keeps sentiment mixed. Analysts: Axon can gain another 30%
• Negative Sentiment: An insider (Isaiah Fields) sold 2,000 shares at roughly $535, trimming his position by ~3.5%; insider selling can be perceived negatively even if modest in size. SEC Filing — Form 4
• Negative Sentiment: Coverage aggregated by TipRanks and others notes multiple insider sales across the company, which can weigh on sentiment if investors interpret the moves as insiders taking chips off the table. Top Axon Insiders Quietly Cash In

Insider Transactions at Axon Enterprise

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the sale, the president owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brittany Bagley sold 2,000 shares of Axon Enterprise stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This represents a 1.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 56,128 shares of company stock worth $31,220,883 in the last three months. 5.70% of the stock is currently owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.